Tirzepatide 10 mg in Europe | Looking to buy Tirzepatide in Europe? LIFE Peptide supplies high-purity Tirzepatide for laboratory research with reliable EU-wide shipping.

Available in two formats

Choose between a conventional lyophilized vial and a dual-chamber cartridge.

The cartridge keeps Tirzepatide and its diluent in separate chambers until activation. This avoids transporting the peptide as a premixed solution and simplifies laboratory preparation by removing the separate liquid-transfer step. Final dual-chamber cartridge concentration: 10 mg in 1 mL. A compatible reusable device is required.

Tirzepatide is a research-grade dual incretin agonist supplied in lyophilised form for laboratory use. It acts on both GLP-1 and GIP receptors and has become a central reference compound in metabolic research, especially in models of appetite regulation, body-weight change, glycaemic control and incretin signalling.

Tirzepatide belongs to a newer class of investigational metabolic peptides designed to engage more than one incretin pathway at the same time, rather than targeting GLP-1 alone. This dual-receptor profile makes it especially relevant in research focused on obesity, glucose homeostasis, insulin signalling, energy balance and next-generation metabolic therapeutics. Tirzepatide is supplied as a lyophilised vial for laboratory and analytical use only.

What is Tirzepatide?

Tirzepatide is an investigational dual incretin receptor agonist designed to activate two key receptor systems involved in metabolic regulation:

GLP-1 receptor
GIP receptor

This receptor profile places Tirzepatide between Semaglutide and Retatrutide in mechanistic breadth. Semaglutide primarily targets GLP-1 alone, while Retatrutide extends beyond GLP-1/GIP into glucagon receptor agonism. Tirzepatide occupies the middle ground: broader than classical GLP-1 analogues, but more selective than triple agonists.

Because of that positioning, Tirzepatide has become one of the most important benchmark compounds in current metabolic research. It is widely used as a comparison point in studies examining single-, dual- and triple-receptor incretin strategies. Lilly and peer-reviewed clinical literature consistently describe Tirzepatide as a once-weekly dual GIP/GLP-1 receptor agonist with strong effects on glycaemic and body-weight outcomes in human studies.

Why Tirzepatide matters in metabolic research

Tirzepatide is important because it combines GLP-1 signalling with GIP receptor activity, creating a broader incretin profile than GLP-1 agonists alone while remaining more focused than triple agonists such as Retatrutide.

In the literature, Tirzepatide has been studied in relation to:

body-weight regulation and appetite signalling
glucose metabolism and glycaemic markers
insulin signalling and nutrient handling
energy balance and systemic metabolic regulation
comparative incretin research across GLP-1, dual agonist and triple agonist models

For researchers building a metabolic peptide panel, Tirzepatide often serves as the central comparator molecule between Semaglutide and Retatrutide. It is one of the clearest examples of how expanding from a single-pathway GLP-1 agonist to a dual incretin agonist can change the metabolic profile under investigation. Your current page already points in this direction; the difference here is that we’re making the comparison logic and search surface much more explicit.

How Tirzepatide works

Tirzepatide is designed to activate two receptor systems involved in metabolic control.

GLP-1 receptor activity

GLP-1 signalling is associated with appetite reduction, delayed gastric emptying and glucose-dependent insulin support. This is the pathway most researchers already know from compounds such as Semaglutide.

GIP receptor activity

GIP signalling is thought to influence insulin secretion, nutrient handling, adipose metabolism and the overall incretin response to food intake. In dual-agonist research, GIP activity is one of the major reasons Tirzepatide is mechanistically broader than GLP-1-only compounds.

Dual incretin profile

The combination of GLP-1 and GIP activity gives Tirzepatide a different metabolic profile from both Semaglutide and Retatrutide. Compared with Semaglutide, it expands the signalling scope beyond GLP-1 alone. Compared with Retatrutide, it remains more selective because it does not include glucagon receptor agonism.

That makes Tirzepatide particularly useful in research focused on:

GLP-1 vs dual agonist comparisons
body-weight and appetite outcomes
glucose homeostasis and insulin dynamics
the transition from single-pathway to multi-pathway incretin modulation

Published clinical findings on Tirzepatide

Tirzepatide has become one of the most closely followed metabolic peptides because published human studies have reported substantial effects on body weight, glycaemic control and broader cardiometabolic markers. In the SURMOUNT-1 trial published in the New England Journal of Medicine, once-weekly Tirzepatide produced dose-dependent reductions in body weight over 72 weeks in adults with obesity or overweight, with the highest-dose arm showing some of the strongest weight-loss outcomes reported at the time for an incretin-based therapy.

Tirzepatide has also shown strong glycaemic effects in type 2 diabetes research. In SURPASS-2, Tirzepatide was compared directly with once-weekly Semaglutide and demonstrated greater HbA1c reduction and greater weight reduction across the studied dose arms. Additional SURPASS studies have further established Tirzepatide as one of the key dual agonists in the current metabolic literature. Your current page already cites the most important trials — SURMOUNT-1, SURPASS-2 and related diabetes work — which is exactly the right evidence base for this section.

Taken together, these trials are the main reason Tirzepatide is so often used as a reference point in modern obesity and diabetes research. It sits at the centre of the comparison between GLP-1 agonists, dual GLP-1/GIP agonists, and newer triple agonist approaches.

Study	Population	Duration	Main published findings
SURMOUNT-1	Adults with obesity or overweight without diabetes	72 weeks	Mean body-weight change was −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg Tirzepatide, respectively, compared with −3.1% with placebo.
SURPASS-2	Adults with type 2 diabetes	40 weeks	HbA1c decreased by −2.01%, −2.24% and −2.30% with Tirzepatide 5, 10 and 15 mg, versus −1.86% with Semaglutide 1 mg. Tirzepatide also produced greater mean body-weight reductions across all three dose groups.
SURPASS-3	Adults with type 2 diabetes inadequately controlled with oral therapy	52 weeks	Tirzepatide produced greater reductions in HbA1c and body weight than insulin degludec across the investigated dose groups.
SURPASS programme	Adults with type 2 diabetes across multiple Phase 3 trials	40–104 weeks	The broader programme established consistent dose-dependent effects on glycaemic control and body weight across different comparator treatments and patient populations.

Important: Results shown above summarize published clinical studies of pharmaceutical Tirzepatide and are provided as research context only. They should not be interpreted as expected outcomes from this research product.

Published safety and tolerability findings

Published clinical studies on Tirzepatide indicate that the most commonly reported adverse events are gastrointestinal, especially nausea, diarrhoea, decreased appetite, vomiting and constipation. As with other incretin-based agents, these events were generally more common than with placebo and were often dose-related, particularly during the dose-escalation phase of treatment.

Across the major clinical programs, most gastrointestinal events were described as mild to moderate in severity, and discontinuation rates were still an important part of how Tirzepatide’s overall profile was evaluated. This is one of the reasons published Tirzepatide research is typically discussed not only in terms of efficacy, but also in terms of tolerability during escalation, GI event burden and the balance between metabolic benefit and dropout risk.

This section summarises published findings on investigational and clinical Tirzepatide research, not instructions or expectations for use of this product.

Published dosing schedules used in Tirzepatide research

Published Tirzepatide studies generally used once-weekly administration with stepwise dose escalation rather than starting at the final target dose immediately. In the major obesity and diabetes trials, Tirzepatide was typically studied at 5 mg, 10 mg and 15 mg maintenance doses, with escalation from a lower starting dose over a period of weeks to improve tolerability. Your current reference list already points to the core trials that established this structure.

In practical terms, the published research design for Tirzepatide is important because it shows that efficacy and tolerability were studied together. Researchers did not simply test “one Tirzepatide dose”; they tested staged escalation strategies leading to different maintenance doses. That is one of the reasons Tirzepatide remains such a useful comparator compound in metabolic peptide research.

Example of the maintenance-dose structure commonly used in major trials

Published study context	Initial dosing approach in the trial	Maintenance dose arms studied	Frequency	Duration
Obesity / diabetes clinical trials	stepwise escalation from lower starting dose	5 mg	once weekly	varied by trial
Obesity / diabetes clinical trials	stepwise escalation from lower starting dose	10 mg	once weekly	varied by trial
Obesity / diabetes clinical trials	stepwise escalation from lower starting dose	15 mg	once weekly	varied by trial

These schedules are included as a summary of published research design and are not instructions for use of this product.

Tirzepatide vs Semaglutide vs Retatrutide

Researchers often compare these three compounds because they sit on the same metabolic spectrum, but they are not interchangeable.

Tirzepatide

Dual agonist: GLP-1 + GIP
Central benchmark for dual incretin research
Often discussed in relation to body-weight outcomes, glycaemic control and incretin signalling

Semaglutide

Single agonist: GLP-1
More selective and mechanistically narrower
Common reference point for GLP-1 pathway research

Retatrutide

Triple agonist: GLP-1 + GIP + glucagon
Broader receptor profile than Tirzepatide
Often discussed in relation to weight loss, energy expenditure and next-generation multi-pathway metabolic modulation

For a detailed comparison of receptor activity, published clinical findings and research differences, read our Retatrutide vs Tirzepatide research comparison.

For researchers comparing incretin classes, Tirzepatide often functions as the middle reference point between single-pathway GLP-1 agonists and broader triple-agonist designs.

Product characteristics

Application: laboratory and analytical research
Use restriction: not for human consumption; not for medical, veterinary or cosmetic use
Produced in GMP-compliant facilities under strict QC protocols.
Each batch carefully lab tested after production (you can find Certificate of Analysis under product pictures).
Freeze-dried (lyophilized) for maximum stability and extended shelf life.
Sealed in sterile vials, ready for reconstitution.
Purity: ≥99% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: 4813.45
Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Storage: unopened lyophilized vials are best stored refrigerated at 2–8°C, which is the storage method confirmed by our manufacturing partner and suitable for up to 24 months. Refrigeration is preferred because it minimizes unnecessary freeze–thaw cycles during routine handling. If substantially longer-term storage is required, unopened lyophilized vials may also be kept frozen. Once reconstituted, always store at 2–8°C and do not freeze.

Independent third-party verification

This batch has undergone additional third-party analytical verification through Janoshik Analytical
Batch: TR10-260423
Internal HPLC purity: 99.13%
Third-party verification: 99.62% independently confirmed high purity and identity consistency. View third-party verification.

Reconstitution and handling

Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with bacteriostatic water before use. GLP-1 class peptides are sometimes slow to dissolve and require very gentle reconstitution to avoid foaming or remaining slightly cloudy.

For other solvent selection, concentration planning and storage guidance, see the full Peptide Reconstitution Guide and Reconstitution Calculator.

Selected research references

Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022.
Frias JP et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2021.
Ludvik B et al. “Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin.” The Lancet, 2021.
Coskun T et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.” Molecular Metabolism, 2018.

Frequently Asked Questions

What kind of peptide is Tirzepatide?

Tirzepatide is an investigational dual incretin agonist designed to activate GLP-1 and GIP receptors.

How is Tirzepatide different from Semaglutide?

Semaglutide primarily targets GLP-1 alone, while Tirzepatide combines GLP-1 and GIP receptor activity, giving it a broader incretin signalling profile.

How is Tirzepatide different from Retatrutide?

Retatrutide is a triple agonist that adds glucagon receptor activity to the GLP-1/GIP profile. Tirzepatide remains more selective as a dual GLP-1/GIP agonist.

What research areas is Tirzepatide associated with?

Tirzepatide has been studied in the literature in relation to body-weight outcomes, appetite regulation, glycaemic control, insulin signalling and incretin biology.

How does Tirzepatide work?

Tirzepatide simultaneously activates GIP and GLP-1 receptors. These incretin pathways influence glucose-dependent insulin secretion, appetite regulation, nutrient handling and energy balance. Its dual-receptor activity distinguishes Tirzepatide from GLP-1-only compounds such as Semaglutide. The FDA describes tirzepatide as selectively binding and activating both GIP and GLP-1 receptors.

What did the SURMOUNT-1 Tirzepatide trial find?

In SURMOUNT-1, mean body-weight reductions after 72 weeks were 15.0%, 19.5% and 20.9% for the 5 mg, 10 mg and 15 mg groups, respectively, compared with 3.1% with placebo. The trial included adults with obesity or overweight without diabetes.

Has Tirzepatide been compared directly with Semaglutide?

Yes. The Phase 3 SURPASS-2 trial directly compared Tirzepatide with Semaglutide 1 mg in adults with type 2 diabetes. Tirzepatide produced greater reductions in HbA1c and body weight across the investigated doses during the 40-week study.

How should lyophilised Tirzepatide be stored?

For this research product, unopened lyophilised vials are best stored refrigerated at 2–8°C. For substantially longer-term storage, unopened vials may also be kept frozen. Avoid unnecessary temperature cycling.

How should Tirzepatide be stored after reconstitution?

Once reconstituted, the solution should be kept refrigerated at 2–8°C and protected from unnecessary temperature fluctuations. Repeated freeze-thaw cycles should be avoided.

Should Tirzepatide be shaken during reconstitution?

No vigorous shaking is required. Gentle handling is preferable when reconstituting peptides, particularly if dissolution is gradual, to minimize foaming and unnecessary mechanical stress.

Why is Tirzepatide called a dual agonist?

Tirzepatide is described as a dual agonist because a single molecule activates two incretin receptor systems—GIP and GLP-1. This contrasts with Semaglutide‘s GLP-1 receptor activity and Retatrutide‘s broader GLP-1/GIP/glucagon triple-agonist profile.

Can I buy Tirzepatide in Europe?

Yes. We ship Tirzepatide to most European countries using reliable courier services. Available shipping methods and delivery times are shown during checkout based on your destination.

Is this product intended for human use?

No. This product is supplied strictly for research use only and is not intended for human consumption or therapeutic use.

Related research context

Tirzepatide is part of the dual incretin receptor agonist (GLP-1/GIP) metabolic research class. For mechanistic comparison with single-pathway GLP-1 agonists and triple-agonist compounds, see our GLP-1 metabolic research guide.

Browse all compounds in the Metabolic research category.

Researchers comparing multi-receptor activation may also examine:

For a detailed comparison of receptor activity, published clinical findings and research differences, read our Retatrutide vs Tirzepatide research comparison.

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
This product is sold for research purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Buyer assumes full responsibility for proper handling and use.

Agonista GLP-1/GIP

Tirzepatida 10 mg